Kulkarni Sandeep Chidambar 4

What Happened

• Sandeep Chidambar Kulkarni, CEO of Zura Bio Ltd (ZURA), was granted an award of 2,934,107 derivative securities on Jan 21, 2026. The filing reports a $0.00 price (no cash paid or sale occurred). This is an equity award (derivative) tied to future vesting rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-21; Form 4 filed: 2026-01-23 (timely filing).
• Security: 2,934,107 derivative shares reported as an award (code A).
• Reported price: $0.00 (no immediate cash outlay reported).
• Shares owned after transaction: not specified in the summary provided (check the full Form 4 for beneficial ownership totals).
• Footnote (vesting): 25% of the award vests on January 21, 2027; the remaining 75% vests in equal quarterly installments thereafter (one-twelfth of the remaining shares each quarter), subject to the CEO’s continuous service.
• Filing does not indicate a 10b5-1 plan, immediate sale, or tax-withholding disposition in the items provided here.

Context

• This is a typical compensation-related equity grant for an executive. Because the award is a derivative grant with a multi-year vesting schedule, it does not reflect an immediate market purchase or sale and should be interpreted as part of long-term compensation rather than a near-term trading signal. For full details (exact beneficial ownership after the grant, award type—e.g., stock options vs. RSUs—and any additional terms), consult the complete Form 4 and the company’s SEC filings.